There ARE numerous vaccine efforts racing across the globe….
Many are in trials already….
But the results from a small American effort has sent the US Stock market on fire…
Bear in mind?
Other efforts are more advanced than the Moderna effort…
But the money for America is on it’s own product….
Oh, and there are already conflict of interest issues…
The drugmaker Moderna said Monday that the first coronavirus vaccine to be tested in people appears to be safe and able to stimulate an immune response against the virus.
The findings, which quickly prompted a rally on Wall Street, are based on results from the first eight people who each received two doses of the experimental vaccine, starting in March.
Those people, healthy volunteers, made antibodies that were then tested in human cells in the lab, and were able to stop the virus from replicating — the key requirement for an effective vaccine. The levels of those so-called neutralizing antibodies matched the levels found in patients who had recovered after contracting the virus in the community.
Limited data from the early phase, however leaves much uncertainty around the vaccine’s potential success.
Moderna’s announcement came just a few days after President Trump named leaders for the federal government’s effort to speed up development of a vaccine, and the company has said that it is proceeding on an accelerated timetable, with the second phase involving 600 people to begin soon, and a third phase to begin in July involving thousands of healthy people. The Food and Drug Administration gave Moderna the go-ahead for the second phase earlier this month.
If those trials go well, a vaccine could become available for widespread use by the end of this year or early 2021, Dr. Tal Zaks, Moderna’s chief medical officer, said in an interview. How many doses might be ready is not clear, but Dr. Zaks said, “We’re doing our best to make it as many millions as possible.”
Despite the uncertainties, the company’s announcement rapidly encouraged investors, who also welcomed a pledge from Jerome H. Powell, the Federal Reserve chair, that there was “really no limit” to what the central bank could do with its emergency lending facilities.
The S&P 500 rose nearly 3 percent in early trading, recouping an entire week’s worth of losses, and Moderna’s shares surged about 20 percent. Stocks in Europe were 3 to 4 percent higher.
Monday’s rally had all the characteristics of one focused on the prospects for a return to normal. Travel stocks, like United Airlines, Expedia Group and Marriott International, were among the best performers in the S&P 500, rising as much as 10 percent….
The front running Oxford University vaccine effort seems to produce a only partial effective vaccine…
The Oxford University vaccine tipped as a “front runner” in the race to develop a coronavirus jab does not stop the virus in monkeys and may only be partially effective, experts have warned.
A trial of the vaccine in rhesus macaque monkeys did not stop the animals from catching the virus and has raised questions about the vaccine’s likely human efficacy and ongoing development.
The vaccine, known as ChAdOx1 nCoV-19, is undergoing human trials in Britain. The Government has brokered a deal between Oxford University and the drug company AstraZeneca to produce up to 30 million doses if it proves successful, having ploughed £47 million into the research.
“All of the vaccinated monkeys treated with the Oxford vaccine became infected when challenged as judged by recovery of virus genomic RNA from nasal secretions,” said Dr William Haseltine, a former Harvard Medical School professor who had a pivotal role in the development of early HIV/Aids treatments.
“There was no difference in the amount of viral RNA detected from this site in the vaccinated monkeys as compared to the unvaccinated animals. Which is to say, all vaccinated animals were infected,” Dr Haseltine wrote in an article on Forbes. …